[{"orgOrder":0,"company":"Incepta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BANGLADESH","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Incepta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incepta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incepta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"R-Pharm","sponsor":"George Mason University | Medsi Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||Interleukin-6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Solution","sponsorNew":"R-Pharm \/ George Mason University | Medsi Group","highestDevelopmentStatusID":"10","companyTruncated":"R-Pharm \/ George Mason University | Medsi Group"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"||RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Montefiore Health System","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"||RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montefiore Health System","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Montefiore Health System \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Montefiore Health System \/ National Institutes of Health"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Lupin Ltd"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ National Institutes of Health"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aclaris Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Aclaris Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aclaris Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Aclaris Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"EGYPT","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eva Pharma \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Eva Pharma \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Eli Lilly"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Natco Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BDR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"BDR Pharmaceuticals \/ Mankind Pharma","highestDevelopmentStatusID":"15","companyTruncated":"BDR Pharmaceuticals \/ Mankind Pharma"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"University of Alabama at Birmingham \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ National Institutes of Health"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BenevolentAI \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BenevolentAI \/ Inapplicable"},{"orgOrder":0,"company":"University of Oxford","sponsor":"UK Research and Innovation | National Institute for Health Research, UK | Wellcome Trust | Bill & Melinda Gates Foundation | DFID UK | Health Data Research UK | Medical Research Council Population Health Research Unit | NIHR Clinical Trials Unit Support F","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Acetylsalicylic Acid","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"University of Oxford \/ UK Research and Innovation | National Institute for Health Research, UK | Wellcome Trust | Bill & Melinda Gates Foundation | DFID UK | Health Data Research UK | Medical Research Council Population Health Research Unit | NIHR Clinical Trials Unit Support F","highestDevelopmentStatusID":"10","companyTruncated":"University of Oxford \/ UK Research and Innovation | National Institute for Health Research, UK | Wellcome Trust | Bill & Melinda Gates Foundation | DFID UK | Health Data Research UK | Medical Research Council Population Health Research Unit | NIHR Clinical Trials Unit Support F"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Duke University","sponsor":"National Institute on Minority Health and Health Disparities | Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Nephrology","graph2":"Phase II","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Duke University \/ National Institute on Minority Health and Health Disparities | Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Duke University \/ National Institute on Minority Health and Health Disparities | Eli Lilly"},{"orgOrder":0,"company":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","sponsor":"Healthcare Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh \/ Healthcare Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh \/ Healthcare Pharmaceuticals"},{"orgOrder":0,"company":"University of North Carolina, Chapel Hill","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"University of North Carolina, Chapel Hill","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"University of North Carolina, Chapel Hill \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"University of North Carolina, Chapel Hill \/ Eli Lilly"},{"orgOrder":0,"company":"Stanford University","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Stanford University \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Natco Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Keck Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Keck Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Keck Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Keck Medicine \/ Inapplicable"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Eli Lilly"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Indian Council of Medical Research \/ University of Oxford","highestDevelopmentStatusID":"1","companyTruncated":"Indian Council of Medical Research \/ University of Oxford"},{"orgOrder":0,"company":"University Hospital, Bordeaux","sponsor":"Eli Lilly | Biogen | Ministry for Health and Solidarity, France","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"University Hospital, Bordeaux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Bordeaux \/ Eli Lilly | Biogen | Ministry for Health and Solidarity, France","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Bordeaux \/ Eli Lilly | Biogen | Ministry for Health and Solidarity, France"},{"orgOrder":0,"company":"Lisa Barrett","sponsor":"Nova Scotia Health Authority | Dalhousie University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Lisa Barrett","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisa Barrett \/ Nova Scotia Health Authority | Dalhousie University","highestDevelopmentStatusID":"8","companyTruncated":"Lisa Barrett \/ Nova Scotia Health Authority | Dalhousie University"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Peking Union Medical College Hospital \/ Eli Lilly"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Eli Lilly"},{"orgOrder":0,"company":"National Taiwan University Hospital","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"National Taiwan University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Taiwan University Hospital \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"National Taiwan University Hospital \/ Eli Lilly"}]
Find Clinical Drug Pipeline Developments & Deals for Baricitinib
Details :
The drug Olumiant (baricitinib) has received restricted emergency use approval from the Central Drugs Standard Control Organization (CDSCO), for use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospita...
Details :
Olumiant (baricitinib) is an oral JAK1/JAK2 inhibitor, small molecule drug candidate, which is being evaluated for the treatment of severe alopecia areata.
Details :
OLUMIANT (baricitinib) is the first and only JAK inhibitor FDA-approved for the treatment of COVID-19 in certain hospitalized adults requiring various degrees of oxygen support.
Details :
The collaboration aims to expand access to Olumiant (baricitinib), an orally-administered, small-molecule, JAK inhibitor, in low- to middle-income countries.
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
